{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:00:49Z","timestamp":1767898849290,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jiac.2023.09.012","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T20:32:14Z","timestamp":1694550734000},"page":"53-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors associated with IgG titers against SARS-CoV-2 spike protein after second vaccination in people living with HIV controlled with anti-retroviral therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Kwangyeol","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-9636","authenticated-orcid":false,"given":"Tetsuya","family":"Horino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-0405","authenticated-orcid":false,"given":"Tokio","family":"Hoshina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0879-033X","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakaharai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-068X","authenticated-orcid":false,"given":"Yasushi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.09.012_bib1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.09.012_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2023.09.012_bib3","article-title":"Effectiveness of the Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region","volume":"26","author":"Fabiani","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jiac.2023.09.012_bib4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2023.09.012_bib5","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1093\/cid\/ciab998","article-title":"Poor antibody response to BioNTech\/Pfizer COVID-19 vaccination in SARS-CoV-2 na\u00efve residents of nursing homes","volume":"75","author":"Pannus","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib6","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/j.ajkd.2003.08.019","article-title":"Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better","volume":"42","author":"DaRoza","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/cid\/ciab580","article-title":"Poor antibody response after two doses of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) vaccine in transplant recipients","volume":"74","author":"Mazzola","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","article-title":"Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis","volume":"159","author":"Tran","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiac.2023.09.012_bib9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib10","doi-asserted-by":"crossref","first-page":"e3465","DOI":"10.1002\/dmrr.3465","article-title":"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine","volume":"38","author":"Watanabe","year":"2022","journal-title":"Diabetes Metabol Res Rev"},{"key":"10.1016\/j.jiac.2023.09.012_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2023.09.012_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12879-020-05593-4","article-title":"Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort","volume":"20","author":"Bonnet","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41581-022-00617-5","article-title":"Vaccination in patients with kidney failure: lessons from COVID-19","volume":"18","author":"Babel","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jiac.2023.09.012_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10157-022-02243-8","article-title":"SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan","volume":"26","author":"Kanai","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jiac.2023.09.012_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065741","article-title":"Humoral response to SARS-CoV-2 vaccination in haemodialysis patients and a matched cohort","volume":"12","author":"Zhao","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2023.09.012_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.922042","article-title":"Long-term humoral response after a second dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients","volume":"13","author":"Ohki","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiac.2023.09.012_bib17","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/ckj\/sfac166","article-title":"BNT162b2 vaccine effectiveness in chronic kidney disease patients\u2014an observational study","volume":"15","author":"Bielopolski","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jiac.2023.09.012_bib18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2215\/CJN.00250117","article-title":"EGFR and the risk of community-acquired infections","volume":"12","author":"Xu","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jiac.2023.09.012_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.ajkd.2014.11.027","article-title":"CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records","volume":"66","author":"McDonald","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep10539","article-title":"Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis","volume":"5","author":"Mansur","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2023.09.012_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.ajkd.2009.04.005","article-title":"CKD and risk of hospitalization and death with pneumonia","volume":"54","author":"James","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib22","first-page":"527","article-title":"Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients","volume":"17","author":"Ghadiani","year":"2012","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.jiac.2023.09.012_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106629","article-title":"Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy","volume":"60","author":"Garcia Garrido","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2023.09.012_bib24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.5812\/kowsar.1735143X.751","article-title":"Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better?","volume":"11","author":"Hashemi","year":"2011","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jiac.2023.09.012_bib25","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1016\/j.vaccine.2005.03.020","article-title":"Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules","volume":"23","author":"McNulty","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2023.09.012_bib26","article-title":"Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV","volume":"8","author":"Liu","year":"2022","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jiac.2023.09.012_bib27","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1016\/j.vaccine.2013.06.012","article-title":"Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"31","author":"Mena","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2023.09.012_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318183a9c0","article-title":"Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study","volume":"49","author":"Launay","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2023.09.012_bib29","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.aids.0000186815.99993.55","article-title":"Response to hepatitis A vaccine in HIV patients in the HAART era","volume":"19","author":"Rimland","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2023.09.012_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.vaccine.2012.12.045","article-title":"Hepatitis A vaccine response in HIV-infected patients: are TWINRIX\u00ae and HAVRIX\u00ae interchangeable?","volume":"31","author":"Jimenez","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2023.09.012_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2893.2006.00822.x","article-title":"Predictors of immunity after hepatitis A vaccination in HIV-infected persons","volume":"14","author":"Overton","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jiac.2023.09.012_bib32","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1086\/516512","article-title":"Response to hepatitis A vaccination in human immunodeficiency virus\u2010infected and \u2010uninfected homosexual men","volume":"176","author":"Neilsen","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1258\/ijsa.2007.007197","article-title":"Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons","volume":"19","author":"Kim","year":"2008","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jiac.2023.09.012_bib34","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1086\/420740","article-title":"Hepatitis A and B vaccination practices for ambulatory patients infected with HIV","volume":"38","author":"Tedaldi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib35","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.ijid.2008.05.1226","article-title":"Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults","volume":"12","author":"Bailey","year":"2008","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib36","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/598193","article-title":"Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients","volume":"48","author":"Evison","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.012_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1681\/ASN.2021091257","article-title":"Secondary immunodeficiency related to kidney disease (SIDKD)\u2014definition, unmet need, and mechanisms","volume":"33","author":"Steiger","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jiac.2023.09.012_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAI.0000000000003000","article-title":"Asymptomatic SARS-CoV-2 infection is common among ART-treated people with HIV","volume":"90","author":"Overton","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2023.09.012_bib39","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.2147\/IDR.S277899","article-title":"HIV and SARS-CoV-2 Co-Infection: what are the Risks?","volume":"14","author":"Squillace","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2023.09.012_bib40","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","article-title":"Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19","volume":"9","author":"Bertagnolio","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2023.09.012_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002666","article-title":"Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study","volume":"34","author":"Hadi","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2023.09.012_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2023.09.012_bib43","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2023.09.012_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2023.09.012_bib45","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3018(21)00099-0","article-title":"Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV","volume":"8","author":"Touizer","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2023.09.012_bib46","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jiac.2023.09.012_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection","volume":"13","author":"Gobbi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2023.09.012_bib48","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.09.012_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jiac.2023.09.012_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019985","article-title":"Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database","volume":"8","author":"Ruzicka","year":"2018","journal-title":"BMJ Open"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:20Z","timestamp":1761159980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1341321X23002179"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with IgG titers against SARS-CoV-2 spike protein after second vaccination in people living with HIV controlled with anti-retroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}